Precision Probiotic Medicine to Improve ICB Immunotherapy

Blanda Di Luccia; Marco Colonna

doi:10.1158/2159-8290.CD-22-0221

Precision Probiotic Medicine to Improve ICB Immunotherapy

Blanda Di Luccia
, Marco Colonna

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Summary: The established impact of gut microbiota-and probiotic-derived metabolites on immune-checkpoint blockade (ICB) has spurred extensive efforts to identify strains and druggable bioactive molecules of microbial origin that can improve tumor immune therapy. In this issue, Kawanabe-Matsuda and colleagues show that the exopolysaccharide EPS-R1 produced by the probiotic strain Lactobacillus delbrueckii subsp. bulgaricus augments the response to ICB therapy by expanding the population of Peyer’s patches CCR6⁺ CD8⁺ T cells, which can subsequently migrate from the gut into CCL20-expressing tumors to enhance antitumor activity.

Original language	English
Pages (from-to)	1189-1190
Number of pages	2
Journal	Cancer discovery
Volume	12
Issue number	5
DOIs	https://doi.org/10.1158/2159-8290.CD-22-0221
State	Published - May 1 2022

Access to Document

10.1158/2159-8290.CD-22-0221

Cite this

@article{aef7d66519914a62b4e9b3f28c8f9c85,

title = "Precision Probiotic Medicine to Improve ICB Immunotherapy",

abstract = "Summary: The established impact of gut microbiota-and probiotic-derived metabolites on immune-checkpoint blockade (ICB) has spurred extensive efforts to identify strains and druggable bioactive molecules of microbial origin that can improve tumor immune therapy. In this issue, Kawanabe-Matsuda and colleagues show that the exopolysaccharide EPS-R1 produced by the probiotic strain Lactobacillus delbrueckii subsp. bulgaricus augments the response to ICB therapy by expanding the population of Peyer{\textquoteright}s patches CCR6+ CD8+ T cells, which can subsequently migrate from the gut into CCL20-expressing tumors to enhance antitumor activity.",

author = "\{Di Luccia\}, Blanda and Marco Colonna",

note = "Funding Information: M. Colonna reports grants and other support from NGM Bio-pharmaceutical and grants from Oncorus during the conduct of the study, as well as grants from Ono, Pfizer, and Aclaris, grants and other support from Vigil Neuro, and other support from Cell Signaling Technology outside the submitted work. No disclosures were reported by the other author. Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",

year = "2022",

month = may,

day = "1",

doi = "10.1158/2159-8290.CD-22-0221",

language = "English",

volume = "12",

pages = "1189--1190",

journal = "Cancer discovery",

issn = "2159-8274",

number = "5",

}

TY - JOUR

T1 - Precision Probiotic Medicine to Improve ICB Immunotherapy

AU - Di Luccia, Blanda

AU - Colonna, Marco

N1 - Funding Information: M. Colonna reports grants and other support from NGM Bio-pharmaceutical and grants from Oncorus during the conduct of the study, as well as grants from Ono, Pfizer, and Aclaris, grants and other support from Vigil Neuro, and other support from Cell Signaling Technology outside the submitted work. No disclosures were reported by the other author. Publisher Copyright: © 2022 American Association for Cancer Research.

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Summary: The established impact of gut microbiota-and probiotic-derived metabolites on immune-checkpoint blockade (ICB) has spurred extensive efforts to identify strains and druggable bioactive molecules of microbial origin that can improve tumor immune therapy. In this issue, Kawanabe-Matsuda and colleagues show that the exopolysaccharide EPS-R1 produced by the probiotic strain Lactobacillus delbrueckii subsp. bulgaricus augments the response to ICB therapy by expanding the population of Peyer’s patches CCR6+ CD8+ T cells, which can subsequently migrate from the gut into CCL20-expressing tumors to enhance antitumor activity.

AB - Summary: The established impact of gut microbiota-and probiotic-derived metabolites on immune-checkpoint blockade (ICB) has spurred extensive efforts to identify strains and druggable bioactive molecules of microbial origin that can improve tumor immune therapy. In this issue, Kawanabe-Matsuda and colleagues show that the exopolysaccharide EPS-R1 produced by the probiotic strain Lactobacillus delbrueckii subsp. bulgaricus augments the response to ICB therapy by expanding the population of Peyer’s patches CCR6+ CD8+ T cells, which can subsequently migrate from the gut into CCL20-expressing tumors to enhance antitumor activity.

UR - https://www.scopus.com/pages/publications/85129781394

U2 - 10.1158/2159-8290.CD-22-0221

DO - 10.1158/2159-8290.CD-22-0221

M3 - Article

C2 - 35491646

AN - SCOPUS:85129781394

SN - 2159-8274

VL - 12

SP - 1189

EP - 1190

JO - Cancer discovery

JF - Cancer discovery

IS - 5

ER -

Precision Probiotic Medicine to Improve ICB Immunotherapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this